





TECHNICAL REPORT ON THE EVALUATION OF THE BIDS EVALUATED BY MEANS OF SUBJECTIVE VALUE-BASED CRITERIA FOR THE CONTRACTING OF A SERVICE OF DNA AND RNA SEQUENCING AND SPECIALIZED BIOINFORMATIC ANALYSIS FROM TUMOR SAMPLES AND WHOLE BLOOD IN THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR).

Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.



## **2025-031 DNA AND RNA SEQUENCING (PI23/01045)**

On 28 August of 2025 has been valued, in accordance with the criteria established in the bidding conditions, the bid submitted by the company participating in this bidding process for the contracting of contracting of the service of Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project PI23/01045 titled "Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo temprano (PORTRAIT-TNBC)" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union.

The tender subject of these minutes, was published in the Contracting Party Profile of our website on 16<sup>th</sup> July of 2025, and the maximum date for the submission of bids according to the minimum deadlines set forth in Law 9/2017, of November 8, Public Sector Contracts, ended on 08<sup>th</sup> August of 2025 at 15:00:00h.

On 18<sup>th</sup> August of 2025, the opening of the envelope containing the bid evaluated by means of criteria subject to value judgment was carried out, as stated in the Minutes of Constitution of the Contracting Committee and of the Opening of Envelope No. 2.

The scoring and motivation of the bids, which have been reproduced considering the specifications contemplated in the Specific Administrative Clauses, shall be detailed below, in accordance with the following scoring table:

## 1 Criteria evaluated by means of value judgment.....(up to 30 points)

The following criteria can be assessed through value judgments. The value will be done in compared with the tenders submitted. The highest score will be given to the offer that best fits the technical requirements set out in this document. All other bids will be scored proportionally by comparison. Subsequently, the various proposals evaluated in descending order will be sorted out, and the following formula will be applied to obtain the score,

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}}$$

 $P_{op}$ = Score the offer to value





P = Criteria score

 $VT_{op}$ = Technical evaluation of the scored offer

 $VT_{mv}$ = Technical evaluation of the best scored offer

The following criteria will be evaluated by value judgments. The award criteria for assessing the contents of Envelope 2 are as follows:

Drafting of work proposal.....(up to 30 points)

The work proposal submitted by the bidders must include at least the following points:

In order to apply the formula set out in Directive 1/2020 on the Application of Formulas for the Evaluation and Scoring of Economic and Technical Proposals, the threshold for each criterion and sub-criterion proposed to be evaluated and subsequently scored is as follows.

Therefore, the minimum scores for each sub-criteria in order to apply the formula will be:

- Detailed report on DNA and RNA sample processing and analysis (quality and quantity) (5 points)
- Detailed report on data analysis (10 points)

There are two possible options regarding the function of this threshold, depending on whether none of the bids exceeds it (option 1) or at least one of the technical bids exceeds it (option 2).

- Option 1 If the evaluation of the bids exceeds the minimum evaluation threshold, all of them obtain as a score the value obtained in the evaluation phase and no bid is excluded from the tender.
- Option 2- If any of the bids exceed the threshold, all the bids are scored and no bid is excluded from the scoring phase, nor from the tender.

In the event that only one tendering company applies for the tendering procedure, the formula presented in the technical aspects will not be applicable for this company, the results obtained after the subjective assessment by the responsible person will be sufficient.



**IMPORTANT NOTE:** In order to be awarded the contract, the tenderer must obtain at least **fifteen (15) points** in the proposal relating to the criteria quantifiable according to value judgements. Otherwise it will be excluded.

In accordance with Clause 12 of the Document of Technical Specifications, on 26<sup>th</sup> August of 2025, a question was sent to bidder company **Sequentia Biotech SL**, requesting it to clarify whether the service related to the sequencing of tumor genomic DNA and normal blood DNA (reference DNA), and the RNA sequencing from the same piece of tumoral tissue will be carried out by the subcontracted company.

After the reply to the clarification within the deadline by the bidder Sequentia Biotech SL, the company replied that the service related to the sequencing of tumor genomic DNA and normal blood DNA (reference DNA), and the RNA sequencing from the same piece of tumoral tissue will be carried out by the subcontracted company.

In accordance with the provisions of Clause 22 of the Document of Technical Specifications:

1. The successful tenderer may only subcontract the partial performance of the contract, which does not constitute the main object of the service tendered for.


Consequently, it is proposed that company Sequentia Biotech SL be excluded for non-compliance of the Clause 22 of the Document of Technical Specifications.

In view of the foregoing, the score that has been achieved is shown below:

Drafting of work proposal.....(up to 30 points)

	Hartwig Medical Foundation	Edinburgh Genetics Limited
Detailed report on DNA and RNA sample processing and analysis (quality and quantity).  The following should be specified: QC Results Summary, etc.	8	5
Up to 10 points		
Detailed report on data analysis. The following should include an outline of the pipeline and details about the tumor characteristics analysed.  Up to 20 points		12

## Justification of the valuations:








For the report on sample processing and analysis Hartwig Medical Foundation (HMF) gets 8 points as it is a very detailed description of the material including source, amount and quality that they consider necessary to ensure good results, and, what is most important, their requirements fall into our availability of material (the samples in this project are both very limited and valuable). On the other hand, Edinburgh Genetics (EG) does not provide any detail on the amount or quality of the samples required and so we give 5 points (no statement of minimum amount required, very general explanation of QC pipeline). We consider a key factor for the quality of the results the fact that HMF has the ISO17025 for the laboratory, as it ensures not only technical competence in testing and calibration, but also a robust quality management system aligned with international standards.

Regarding the data analysis report, in the case of HMF, there is a detailed description of every aspect, with informative details and links to the open-source analytical pipeline in GitHub for us to check while EG gives a more general description of the bioinformatics packages and pipelines they would use. As commented, HMF gives an itemized list of every analysis they would perform and in the case of HMF a link for very detailed information on the pipelines on GitHub repository, while EG gives a shallow description. That level of transparency supports reproducibility and allows for early evaluation of methodological soundness. HMF also offers the expertise of clinical molecular biologists in pathology to contribute to diagnostic, which in this context is a complementary but relevant addition to the analysis. For this reason, HMF receives 16 points. The information EG presents limits the ability to assess the robustness or relevance of their pipeline for the objectives of our project. As such, EG scores 12 points.







Consequently, the scoring table for the value judgement criteria is as follows:

VALUE JUDGEMENT TABLE			
Bidders:	30% - Value Judgement		
Hartwig Medical Foundation	24,00		
Edinburgh Genetics Limited	17,00		

Once the bidding companies have been evaluated and the scores have been arranged in descending order, the following formula is applied to obtain the score for each item evaluated,

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}}$$

Pop= Score of the offer to be scored.

P= Score of the criterion

VTop= Technical Evaluation of the Bid to be Scored.

VTmv= Technical Evaluation of the Highest Scored Bid.

Drafting of work proposal.....(up to 30 points)

	Hartwig Medical Foundation	Edinburgh Genetics Limited
Detailed report on DNA and RNA sample processing and analysis (quality and quantity).  The following should be specified: QC Results Summary, etc.	10,00	6,25
Up to 10 points		
Detailed report on data analysis. The following should include an outline of the pipeline and details about the tumor characteristics analysed.	20,00	15,00
Up to 20 points		

Consequently, the definitive score table for the value judgement criteria is as follows, after application of the formula:

DEFINITIVE VALUE JUDGEMENT TABLE			
Bidders: 30% - Value Judgement			
Hartwig Medical Foundation	30,00		
Edinburgh Genetics Limited	21,25		



Below is the table of scores for the technical offers, which will be completed with the economic part presented by each company, once the public opening of envelope No. 3 takes place, which will be on 03rd of September of 2025 at 10:00 am, announced in the bases of this tender published on the website of the VHIR.

SCORE BOARD							
				56%	14%	30%	
Offers submitted:	Economic Offer			Economic Offer	Automatic Evaluation criteria	Value Judgment	
	BI	VAT	TOTAL				TOTAL
Hartwig Medical						20.00	
Foundation						30,00	
<b>Edinburgh Genetics</b>						04.05	
Limited						21,25	
Sequentia Biotech						-	
OL .							

Barcelona, 28 August of 2025.

## Dr. Ana Mafalda Antunes de Melo Oliveira

IP of the Project PI23/01045

Clinical Research Scientist and Medical Oncologist in the Breast Cancer Group at VHIO Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca